Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2- breast cancer

Conclusion: High CCNE1 levels were confirmed as a biomarker of resistance to letrozole+palbociclib. Ki67 recovery within 3-9 days of discontinuing palbociclib indicates incomplete suppression of proliferation during the "off" week of its schedule.PMID:34645649 | DOI:10.1158/1078-0432.CCR-21-1628
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research